Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD (JAK-FMT)

St. Petersburg State Pavlov Medical University

Status and phase

Terminated

Phase 2

Phase 1

Conditions

Intestinal GVHD

Treatments

Drug: Ruxolitinib

Biological: allogeneic fecal microbiota

Drug: Methylprednisone

Study type

Interventional

Funder types

Other

Identifiers

NCT04269850

tfm-gvhd-2019

Details and patient eligibility

About

Therapy of severe intestinal graft-versus-host disease (GVHD) despite the introduction of novel target agents is associated with worse outcome compared to the other forms. Response to steroids is observed only in about 10% of patients. The most promising approaches are JAK inhibition and fecal microbiota transplantation. In this pilot study we evaluate this combination treatment in the first line.

Full description

Acute intestinal GVHD grade III-IV after allogeneic stem cell transplantation the form with low effectiveness of corticosteroids. Despite high response rate to systemic immunosupressive agents, long term survival in this group is poor due to recurrent septic episodes and gut colonization with multidrug resistant bacteria. Fecal microbiota transplantation (FMT) from a healthy allogeneic donor, allows to restore numerous local and systemic microbiota functions, including immunomodulation and thus to reduce/stop the manifestations of GVHD. The therapeutic mechanism of action of FMT is based on competition for nutrients between obligate and pathologic bacterial strains, direct growth inhibition of the pathological pathogens, host immune system modulation, especially T-reg homeostasis, through interaction with the normal microbiota.In this pilot trial we combine FMT with ruxolitinib and steroids, one of the most effective option for refractory GVHD.

Enrollment

2 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 5-70 years
Histologically confirmed gastrointestinal acute GVHD
Grade III-IV gastrointestinal GVHD based on 2016 MAGIC criteria
Ability for oral drug intake
Signed informed consent

Exclusion criteria

Requirement for oxigen and/or vasopressor support
Respiratory distress >grade I
Severe organ dysfunction: AST or ALT >5 upper normal limits, bilirubin >1.5 upper normal limits, creatinine >2 upper normal limits,creatinine clearance < 60 mL/min
Ongoing fluconazole therapy
Any malignancy requiring systemic therapy at the time of enrollment
Mixed chimerism at last evaluation
Uncontrolled bacterial or fungal infection at the time of enrollment
Requirement for vasopressor support at the time of enrollment
Karnofsky index <30%
Severe concurrent illness that can interfere with study procedures
Somatic or psychiatric disorder making the patient unable to sign informed consent